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Background: Smokers have increased cell concentration in the lower respiratory tract indicating a chronic
inflammatory state, which in some individuals may lead to development of chronic obstructive pulmonary disease
(COPD). Computer tomography (CT) imaging provides means of quantifying pulmonary structure and early signs of
disease. We investigated whether lung density on high resolution CT differs between smokers and never-smokers
and if this were associated to intensity of inflammation.
Methods: Forty smoking volunteers with normal pulmonary function, 40 healthy never-smokers and 40 patients
with COPD of GOLD stage I-II, were included. Mean lung attenuation and percentage of pixels in the lung with
attenuation between −750 and −900 HU (percentage higher density spectrum (%HDS)) were calculated on inspiratory
CT-scans. Markers of systemic inflammation in blood and cell counts in bronchoalveolar lavage (BAL) fluid were
recorded.
Results: Lung density expressed as %HDS was increased in smokers (44.0 ± 5.8%) compared to both never-smokers
(38.3 ± 5.8%) and patients with COPD (39.1 ± 5.8%), (p < 0.001, for both). Females had denser lungs than males, which was
dependent on body height. Cell concentration in BAL were correlated to lung density in smokers (r = 0.50, p < 0.001).
Conclusions: Lung density on CT is associated with cell concentration in BAL in smokers and may mirror an
inflammatory response in the lung. Gender difference in lung density is dependent on height. In COPD with emphysema,
loss of lung tissue may counterbalance the expected increase in density due to inflammation. The findings may help to
interpret high resolution CT in the context of smoking and gender and highlight the heterogeneity of structural changes
in COPD.
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Cigarette smoke induces an inflammatory reaction in the
lung and is a major risk factor for a number of lung dis-
eases such as chronic obstructive pulmonary disease
(COPD) and diffuse parenchymal lung diseases [1]. Fur-
ther, cigarette smoking leads to elevation of both cells and
soluble markers of systemic inflammation in the circula-
tion [2]. Infiltration of macrophages and mononuclear* Correspondence: reza.karimi@ki.se
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unless otherwise stated.cells in the lung leads to tissue damage and release of nu-
merous inflammatory mediators resulting in an increased
epithelial permeability and oedema in the lung intersti-
tium [3]. Both local and systemic inflammation in smokers
may be present before any significant clinical symptoms
appear [2].
Computer tomography (CT) imaging of the lung can
non-invasively detect and quantify lung abnormalities
[4-7]. Early changes in airways and lung parenchyma
may be recognized in smoking individuals with normal
pulmonary function before any signs of lung function
impairment [8,9]. In CT scans, attenuation is measured
by Hounsfield Units (HU), where attenuation for watertd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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authors have focused on the region of the lung with low at-
tenuation i.e. <−910 or −950 HU as a quantitative assess-
ment of emphysema. These studies are usually performed
on subjects with advanced emphysema or on heavy smo-
kers included in lung cancer screening programs [10-12].
Despite the potential of CT to non-invasively detect and
quantify early subclinical pathological changes such as in-
creased density, studies in this field are scarce.
Given the intense systemic and local inflammation in-
duced by smoking, we asked whether this may be mir-
rored by alterations in the high density spectrum assessed
by high resolution CT. We therefore hypothesized that
lung density were associated with an inflammatory re-
sponse, and to test this a group of smokers with normal
pulmonary function, a matched group of healthy never-
smokers and a group of patients with COPD (GOLD I-II)
underwent inspiratory CT examinations. The percentage
of the lung parenchyma in the high density spectrum, i.e.
with attenuation between −750 to −900 HU (%HDS) was
calculated within pre-defined thresholds. We also analysed
blood samples and performed bronchoscopy and broncho-
alveolar lavage for cell concentrations and differential cell
counts as measures of systemic and local inflammation.
Materials and methods
Subjects
The study was performed as a part of the Karolinska COS-
MIC study [13,14] comprising 120 individuals in the age
45–65 years and matched for gender (20/20 per group) con-
sisting of healthy never-smokers, smokers with normal lung
function, and COPD patients (GOLD, I-II). Of the COPD
patients, 28 were current smokers and 12 ex-smokers with a
period since smoking cessation of more than 2 years. A
medical examination and a posteroanterior and lateral chest
X-ray were performed. Subjects with any significant medical
condition or lung parenchymal abnormality except COPD
on the chest X-ray or CT- scans were excluded. Subjects
with asthma, allergy or airway infection were not included,
and no one used inhaled or oral corticosteroids or had an
exacerbation during at least 3 months prior to inclusion.
All subjects completed a self-administered questionnaire
(Chronic Respiratory Questionnaire, CRQ). Blood samples
were obtained by venipuncture, and high sensitive C-
reactive protein (CRP), orosomucoid, haptoglobin, immu-
noglobulin G and white blood cells counts were analysed
according to routine standard methods at the Depart-
ment of Clinical Chemistry, Karolinska University Hospital,
Stockholm, Sweden.
Lung function
Forced expiratory volume in one second (FEV1) and
forced vital capacity (FVC) were measured 20 minutes
after bronchodilatation with two inhalations of 0.5 mgTerbutalin (Bricanyl® Turbuhaler®; AstraZeneca, Södertälje,
Sweden) using a spirometer (Vmax 229–6200 Legacy,
USA). Total lung capacity (TLC) and residual volume
(RV) were measured by body plethysmography. Carbon
monoxide diffusing capacity (DLco) was measured by
the single breath method and corrected for haemoglobin.
Measurements were expressed as percentage of predicted
values according to the European Community of Coal and
Steel [15,16].
Computed tomography (CT) imaging
Non-contrast enhanced, multi-detector helical CT ex-
aminations were performed using a Siemens Somatom
sensation 16 slice CT (Siemens, Erlangen, Germany).
Scans were done in a supine position and covered the
entire chest during full inspiration. The scanning param-
eters were 16 × 0.75 mm collimation, 120 kV, rotation
time 0.5 s and pitch 1.5. Dose modulation was used
resulting in a mean of 180 mA. Axial images with 1 mm
thickness and 0.5 mm overlap were reconstructed with
filtered back projection and a medium high spatial reso-
lution algorithm (B60f) in a 512 × 512 matrix.
Image analysis
CT images were analysed using a semiautomatic program
(Volume, Siemens), which automatically recognizes the lung
borders and segments it from surrounding thoracic tissues
by selecting pixels within determined attenuation limits
from a seeding point. Attenuation values between −300
to −1024 HU were considered to delimit the lung paren-
chyma from surrounding structures and larger arteries.
Mean lung attenuation and lung volume were measured
automatically. The measured values are the mean of density
of air in alveoli and the surrounding epithelial, capillary and
extracellular matrix and small airways. Increased oedema
and accumulation of the inflammatory cells would increase
the density, and destruction of alveolar walls and loss of tis-
sues such as in emphysema would decrease the density.
The lung tissue was then further divided by adding the
pixels within pre-defined CT attenuation limits in volumes
and was then expressed as percentage of the entire lung
volume [4,17]. Volumes in the range -300 to -750 HU
were considered to represent pixels including tissue such
as small bronchi, vessels and borders with denser struc-
tures (partial volume effect) and were analysed separately.
Since measurements of parenchymal inflammation were
the objective of the study, we focused on the areas be-
tween -750 and -900 HU, designated % high density
spectrum (%HDS), representing lung tissue in the denser
normal range. The lower limit was set to −900 HU based
on previous studies which have shown that attenuation
values less than −900 HU corresponds to macroscopic
emphysema both in pathological specimens and in visual
assessment of CT-scans [18,19].
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Bronchoscopy with bronchoalveolar lavage was per-
formed in order to obtain cells from the distal airways.
Bronchoscopy procedure and preparation of BAL cells
were performed according to a standard procedure in
our department described in detail previously [20].
Briefly, the bronchoscope was wedged in a middle lobe
segment bronchus and 5 aliquots of phosphate-buffered
saline of 50 mL each were instilled. The volume of the
recovered BAL fluid was measured and the recovery per-
centage was calculated. A cell pellet was obtained after
centrifugation, and cell counts were prepared using a
Bürker Chamber (Marienfeld, Germany). Cytospin slides
were analysed after staining with May-Grünwald Giemsa
and 500 cells were counted. Results were reported as
both total cell count and cell concentration.
Statistical analysis
Data were tested for normality using Bartlett’s test and
one way analysis of variance (ANOVA) was utilized for
univariate statistical testing. Bonferroni adjustment was
employed for multiple testing compare mean values be-
tween groups. Bivariate analysis was conducted with
two-tailed unpaired t-test for continuous variables. The
values were expressed as mean and SD. Univariate linear
regression were employed to evaluate relationship be-
tween %HDS and mean lung attenuation with potential
covariates. Only significant covariates were then in-
cluded in a multiple linear regression model. Statistical
significances was defined as p values <0.05. All statistical
analysis were performed using Stata12 software (Stata
Corp, College Station, TX, USA).
Ethical statement
Signed informed consent was obtained from all volun-
teers after verbal and written information. The study
was approved by the Regional Ethical Review Board in
Stockholm Sweden (dnr. 2006/959-31/1) and the Radi-




Demography, lung function, markers of systemic inflam-
mation and BAL data are outlined in Table 1 and the
COPD group divided into current smokers and ex-
smokers in Table 2. The three investigated groups were
well matched regarding body mass index (BMI) and
height. The COPD patients were slightly older than the
smokers, but the smoking history was similar. Criteria
for chronic bronchitis [21] were fulfilled for eleven of
the smokers and for nine of the COPD patients. Diffu-
sion capacity for carbon monoxide (DLCO) was signifi-
cantly lower in the COPD group and in the smokergroup compared to the never-smokers. COPD patients
had significantly higher CRQ dyspnoea score than
smokers and never-smokers (p < 0.001 for both). The
COPD ex-smokers had smoked less than the COPD
current smoker group and had a higher body mass index
(BMI). There were no significant differences between
males and females regarding age, BMI, smoking history
and pulmonary functions parameters (data not shown).
Lung density expressed as mean lung attenuation and %HDS
Smokers had denser lungs than both never-smokers and
COPD patients (Figure 1) resulting in a shift of lung
attenuation values to a higher density (Figure 2). The
mean lung attenuation was higher for smokers (−857 ±
28 HU; mean ± SD) than for never-smokers (−874 ± 20
HU) and patients with COPD (−876 ± 17 HU), (p < 0.001
for both). This was also reflected when lung density
was quantified as %HDS; smokers (44.0 ± 5.8%), never-
smokers (38.3 ± 5.8%) and COPD patients (39.1 ± 5.8%),
(p < 0.001 for both), (Figure 3). There were no signifi-
cant differences in lung density between the entire
group of COPD patients and never-smokers.
When the COPD patients were divided into current
smokers and ex-smokers, there was no difference in %HDS
between COPD current smokers and smokers with normal
lung function (p = 0.2). However, %HDS was significantly
lower in COPD ex-smokers (33.1 ± 4.5%) compared to both
COPD current smokers and smokers (p = 0.04 for both).
Areas with a density of −300 to −750 HU were calcu-
lated separately since this may represent pixels including
non-parenchymal tissue such as bronchi and vessels.
The percentage of lung in this spectrum was not signifi-
cantly different between smokers (13.9% ± 6.1), never-
smokers (12.5% ± 4.6) and COPD patients (11.1% ± 2.2).
Difference in lung density between genders
Never smoking and smoking females had higher lung
density measured as %HDS, (40 ± 1.3%) and (46 ± 1.1%)
respectively compared to never-smoking and smoking
males (36 ± 1.3%) and (42 ± 1.2%) and (p < 0.03 and p <
0.04), (Figure 4). There was no significant difference in
lung density between males and females in the COPD
group (data not shown). In a multiple regression model,
after adjustment for height and total lung capacity these
differences between genders were not able to demon-
strate (data not shown).
Correlations between lung density and measures of
systemic inflammation
White blood cell count was significantly higher both in
smokers and in COPD-patients compared to never-
smokers as were the concentrations of orosomucoid and
haptoglobin in serum. C-reactive protein was, however,
significantly increased only in the COPD patients (Table 1).
Table 1 Demographics, lung function and markers of systemic and local inflammation in never smokers, smokers
and COPD patients
Variables Never smokers Smokers COPD
N (male/female) 40 (20/20) 40 (20/20 40 (20/20)
Age 57.0 ± 7.0 54.0 ± 6.2 59.2 ± 5.3¤
Body mass index (kg/m2) 25.9 ± 3.7 24.3 ± 3.1 25.3 ± 4.1
Height (centimetres) 172 ± 10.0 172 ± 10.8 171 ± 7.6
Smoking history (pack years) N/A 35.2 ± 12.4 38.0 ± 11
Cigarette/day (last 6 months) N/A 17.8 ± 6.6 16.4 ± 6.4
FEV1 (% predicted) 118.4 ± 12.8 109.5 ± 11.9
$$ 78.9 ± 11.7$$$, ¤¤¤
FVC (% predicted) 101.2 ± 10.7 96.9 ± 11.1 88.3 ± 12$$$, ¤¤¤
FEV1/FVC 0.82 ± 5.4 0.78 ± 4.7 0.61 ± 6.4
$$$, ¤¤¤
DLco (% predicted) 90.9 ± 10.8 77.9 ± 12.2$$$ 66.7 ± 13.0$$$, ¤¤¤
TLC (% predicted) 106 ± 10.7 106.8 ± 11.1 108.2 ± 14.8
RV (% predicted) 102.1 ± 25.3 112.9 ± 22.5 138.0 ± 33.6$$$, ¤¤¤
Chronic bronchitis (% of individuals) 0 25$$$ 23$$$
Dyspnea score (CRQ) 6.8 ± 0.5 6.4 ± 0.77 6.0 ± 0.85$$$, ¤¤
White blood cell count (109/L) 5.7 ± 1.1 7.4 ± 1.6$$$ 7.7 ± 1.9$$$
Serum-high sensitive-CRP (g/L) 1.2 ± 0.89 1.9 ± 1.8 3.0 ± 2.7$$$, ¤¤
Serum-orosomucoid (g/L) 0.69 ± 0.12 0.78 ± 0.18$ 0.84 ± 0.16$$$
Serum-haptoglobin (g/L) 0.88 ± 0.37 1.2 ± 0.50$$$ 1.4 ± 0.46$$$
Serum-immunoglobulin G (g/L) 11.1 ± 2.0 9.1 ± 1.8$$$ 9.6 ± 1.8$$$
BAL cell concentration (106/L) 121.0 ± 49.8 557.0 ± 230$$$ 378.3 ± 277$$$, ¤¤¤
BAL macrophages (106/L) 103.4 ± 40.3 535.4. ± 160$$$ 358.0 ± 272$$$, ¤¤¤
BAL lymphocytes (106/L) 15.6 ± 17.6 14.1 ± 12.0 13.2 ± 8.8
BAL neutrophils (106/L) 1.8 ± 1.6 4.6 ± 5.3$$ 4.1 ± 3.7$$
BAL eosinophils (106/L) 0.27 ± 0.53 1.5 ± 3.0 2.5 ± 8.2
BAL recovery (%) 64.5 ± 11.8 58.4 ± 10.7 45.8 ± 14.3$$$, ¤¤¤
Values are expressed as mean and SD unless otherwise stated.
COPD = chronic obstructive pulmonary diseases; N/A = not applicable; kg = kilogram; m =meter; FEV1 = forced expiratory volume in 1 s; FVC = forced vital capacity;
TLC = total lung capacity; RV = residual volume; DLco = carbon monoxide diffusing capacity; BAL = bronchoalveolar lavage; CRQ = chronic respiratory questionnaire;
g = gram; L = liter. ¶ = only current smokers COPD.
$p ≤ 0.05, $$p ≤ 0.01, $$$p ≤ 0.001 for comparison with never smokers; ¤p ≤ 0.05, ¤¤p ≤ 0.01, ¤¤¤p ≤ 0.001 for comparison with smokers.
Karimi et al. Respiratory Research 2014, 15:23 Page 4 of 10
http://respiratory-research.com/content/15/1/23The concentration of Immunoglobulin G was lower in
current smokers and COPD patients. Current smoking
COPD patients had significantly higher concentration of
haptoglobin than COPD ex-smokers (Table 2). There was
a significant positive correlation between lung density (%
HDS) and haptoglobin in serum in both smokers and
COPD patients, while immunoglobulin G had negative
correlation in smokers and COPD (Table 3). There was no
significant correlation between lung density and other
markers of systemic inflammation measured in serum.
Correlations between lung density and measures of local
inflammation
Total cell and macrophage concentrations in BAL were
higher in current smokers than in never-smokers and
COPD ex-smokers (Table 1). The BAL-recovery, measured
as percentage of recovered fluid, was significantly higher infemale smokers with normal lung function than in their
male counterparts. There were no any other significant dif-
ferences between males and females in any other BAL par-
ameter (data not shown).
The increase in cell concentration in the COPD group
was mainly determined by COPD current smokers (Table 2).
The concentration of neutrophils did not differ between
smokers with normal lung function and COPD patients, al-
though both groups had higher concentration than never-
smokers.
There was a positive correlation between lung density
(%HDS) and total cell concentration in BAL both for
smokers with normal lung function (r = 0.38, p = 0.03)
and when smoking COPD patients were included (r =
0.50, p < 0.001) (Table 3 and Figure 5). There was no
correlation between cell concentration in BAL and lung
density in never-smokers.
Table 2 Demographics, lung function and markers of
systemic and local inflammation In COPD patients





N (male/female) 28 (15/13) 12 (5/7)
Age 58.9 ± 5.1 59.8 ± 5.9
Body mass index (kg/m2) 24.1 ± 3.8 27.7 ± 4.0$
Height (Centimetres) 172 ± 1.4 170 ± 2.5
Smoking (pack years) 41.6 ± 10.4 29.1 ± 8.9$$$
Cigarette per day (last 6 months) 16.4 ± 6.4 N/A
Time since smoking cessation years
(range)
N/A (2–16)
FEV1 (% predicted) 79.4 ± 10.8 78.1 ± 14.0
FEV1/FVC 0.61 ± 5.9 0.61 ± 7.8
DLco (% predicted) 66.3 ± 12.1 67.6 ± 15.3
TLC (% predicted) 107.6 ± 16.5 109.6 ± 10.4
RV (% predicted) 137.6 ± 36.9 138.8 ± 25.9
Chronic bronchitis (% of individuals) 25 17
Dyspnoea score (CRQ) 5.9 ± 0.91 6.1 ± 0.72
White blood cell counts (109/L ) 8.0 ± 1.9 7.0 ± 1.9
Serum -high sensitive-CRP (g/L) 3.2 ± 3.0 2.7 ± 1.9
Serum -orosomucoid (g/L) 0.86 ± 0.18 0.80 ± 0.12
Serum -haptoglobin (g/L) 1.5 ± 0.45 1.1 ± 0.36$$
Serum -immunoglobulin G (g/L) 9.4 ± 1.7 10.3 ± 2.7
BAL cell concentration (106/L) 492.5 ± 255.3 118.6 ± 69.1$$$
BAL macrophages (106/L) 470.9 ± 250.0 101.2 ± 64.0$$$
BAL lymphocytes (106/L) 13.1 ± 9.0 14.4 ± 8.4
BAL neutrophils (106/L) 4.7 ± 4.1 2.7 ± 2.1
BAL eosinophils (106/L) 3.5 ± 1.9 0.23 ± 0. 13
BAL recovery (%) 43.7 ± 14.8 50.4 ± 12.2
Values are expressed as mean and SD unless otherwise stated.
COPD = chronic obstructive pulmonary diseases; N/A = not applicable;
kg = kilogram; m =meter; FEV1 = forced expiratory volume in 1 s; FVC = forced
vital capacity; TLC = total lung capacity; RV = residual volume; DLco = carbon
monoxide diffusing capacity; BAL = bronchoalveolar lavage; CRQ = chronic
respiratory questionnaire; g = gram; L = liter.
$p ≤ 0.05, $$p ≤ 0.01, $$$p ≤ 0.001.
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smoking history, BMI, age and height
In the COPD patients, total lung capacity (TLC) and re-
sidual volume (RV) were both negatively correlated to
lung density measured as %HDS (Table 3). In a multivari-
ate model, TLC showed a significant negative association
with lung density in never-smokers (R2 = 31, parameter
estimate −0.95; 95% CI −0.70 to −0.11; p = 0.007) and
in COPD patients (R2 = 64; parameter estimate −0.17;
95% CI −0.28 to −0.07; p = 0.001) but not in smokers with
normal lung function. Current cigarette consumption,
measured as numbers of cigarettes per day, was corre-
lated to %HDS, (r = 0.41; p = 0.008), but there was nocorrelation to cumulative smoking history expressed as
pack years. %HDS was negatively correlated to height in
never-smokers and smokers but not in COPD patients.
Age and BMI did not correlate to lung density.
Correlation between lung volumes measured by CT and
body plethysmography
Agreement between lung volumes measured by CT and
body plethysmography is expressed graphically in Figure 6
for all subjects; the correlation coefficient was 0.9 (p <
0.001). There were no significant difference regarding level
of inspiration between never-smokers, smokers and
COPD-patients.
Discussion
In this study we aimed to quantify the impact of chronic
cigarette smoking on lung density on HRCT by studying
smokers with normal lung function and COPD patients.
We demonstrated that lung density was positively corre-
lated to measures of local inflammation, i.e. the total cell
concentration as well as concentrations of macrophages
and neutrophils in BAL. In addition, females had denser
lungs than males, regardless of smoking habits.
Earlier morphological studies on the lung of smokers
have revealed that inflammation in small airways and lung
parenchyma precedes architectural distortion and emphy-
sema [8,16,22] and Remy-Jardin et al. [23] demonstrated
that early subtle parenchymal inflammation in normal
smokers correlated to development of emphysema. Our
findings with increased lung attenuation in smokers are in
line with previous reports [12,23-25], although few studies
have been performed including healthy never-smokers.
Lederer et al. [24] reported a positive correlation between
lung density and cumulative and current smoking history.
Shaker et al. [12] reported a significantly increased lung
density in current smokers which decreased after smoking
cessation [26]. During a 5-year follow-up, Soejima et al.
[25] found that the density on inspiratory CT increased in
smokers compared to never-smokers while it decreased
after smoking cessation.
Cigarette smoking induces a dose-related inflammatory
response in the lungs with accumulation of macrophages
and neutrophils into the lower respiratory tract [27,28]. In
agreement with these previous reports, we found that the
numbers of macrophages and neutrophils were signifi-
cantly raised in smokers with normal lung function and
in current smoking COPD patients. The inflammatory
process seems to be reversible, at least in terms of these
parameters, since COPD ex-smokers exhibited cell num-
ber in BAL fluid equal to those of never-smokers.
We demonstrated a positive correlation between lung
density and cell concentration in BAL fluid both in smokers
with normal lung function and in current smoking COPD
patients. Lung density does not solely depend on the
Figure 1 Axial inspiratory CT scans at the level of right inferior pulmonary vein, from three 54 year old females, representing typical
patterns; Left panel: healthy never-smoker; Middle panel: smoker (note subtle uniform diffuse increased opacity which makes vessels
more visible and mild interlobular septal thickening, especially in middle lobe; Right panel: COPD (note diffusely distributed centrilobular
emphysema, more in central part of scans, with radiolucency and irregular vascular pattern).
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stitium but may also depend on other factors such as
oedema and peribronchiolar fibrosis. We consider,
however, that cell concentration in BAL fluid could be
regarded as an overall indicator of the inflammatory
process in the lung. The fact that DLCO was reduced
in smokers with normal lung function suggests an in-
creased barrier for oxygen diffusion due to inflammation
in the alveolar interstitium rather than reduced area for
gas exchange due to emphysema, while the latter may be
dominant in COPD patients.
An interesting finding is that lung density in our entire
group of COPD patients was lower than the smokers’
and did not differ from never-smokers. A plausible ex-
planation may be that areas with decreased lung density
in COPD patients (i.e. emphysema) and areas withFigure 2 Histogram showing relationship between lung density measur
smokers and COPD patients).increased lung density (i.e. accumulation of inflamma-
tory cells) may occur in the same patient but in different
regions of the lung. This results in an average density in
the COPD-patients’ whole lung, that does not differ
from never-smokers. When the COPD patients were
sub-grouped in ex-smokers and current smokers, the lat-
ter had higher density. This suggests that inflammation
due to smoking (i.e. increased lung density) overshadows
potential reduction in lung density due to parenchymal
destruction. In COPD ex-smokers, the absence of smoke-
induced cell infiltration in the lower airways results in a
lower density, probably due to parenchymal destruction
and emphysema. This hypothesis is also supported by our
finding that total cell concentration in BAL fluid was sig-
nificantly lower in COPD ex-smokers than in COPD
current smokers.ed as attenuation −750 HU to −900 HU (%HDS) for (never-smokers,
Figure 3 Lung density, measured as percentage of lung volume
with attenuation −750 to −900 HU (%HDS) for never-smokers
(NS), smokers (S), COPD current smokers (COPD-cs) and COPD
ex-smokers (COPD-es).
Table 3 Pearson correlations coefficients between %HDS
and differential cell count in BAL, serum proteins, lung
function, smoking status and demographic data
Variables Never smokers Smokers COPD
BAL cell concentration (106/L) - 0.38$ 0.57$$$
BAL macrophages (106/L) - 0.36$ 0.57$$$
BAL lymphocytes (106/L) - 0.41$$ -
BAL neutophils (106/L) - 0.47$$ 0.40$
Serum-haptoglobin (g/L) - 0.37$ 0.32$
Serum-immunoglobulin G (g/L) - −0.50$$ −0.41$
TLC (% predicted) −0,52$$$ - −0.39$
RV (% predicted) −0,33$ - −043$$
FEV1 (% predicted) - - -
DLco (% predicted) - - -
Smoking history (pack years) - - -
Cigarette per day (last 6 months) - - 0.41$$
Height −0.40$$ −0.32$ -
COPD = chronic obstructive pulmonary diseases; BAL = bronchoalveolar lavage;
L = liter; g = gram; FEV1 = forced expiratory volume in 1 s; TLC = total lung
capacity; RV = residual volume; DLco = carbon monoxide diffusing capacity;
BMI = body mass index.
Values are expressing correlations coefficients.
$p ≤ 0.05, $$p ≤ 0.01, $$$p ≤ 0.001.
- Not statistically significant.
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grade of systemic inflammation indicated by elevated
serum markers [2,29]. We found significantly higher levels
of white blood cells, orosomucoid and haptoglobin but de-
creased level of immunoglobulin G in serum of smokers
and COPD patients compared to never-smokers. In
smokers and COPD patients, lung density was positively
correlated with the concentration of haptoglobin in serum,
but not to C reactive protein (CRP). Haptoglobin is an
acute phase protein which is elevated in inflammatory andFigure 4 Lung density, measured as percentage of lung volume
with attenuation −750 to −900 HU (%HDS) for never-smokers
(NS) and smokers (S) separated into males and females.infectious conditions and may be a sensitive marker for
low grade systemic inflammation. The levels of immuno-
globulin G were significantly lower in smokers and in
COPD current smokers compared with never-smokers,
which reassures an immunosuppressive effect of cigarette
smoking [30].
Previous reports have shown gender differences for
lung function impairment and symptoms related to
smoking [31-33]. Dransfield et al. [34] reported that theFigure 5 Correlation between percentage of lung volume with
attenuation −750 to −900 HU (%HDS) and cell concentration in
BAL for current smokers.
Figure 6 Relationship between total lung volume measured by
CT and total lung capacity measured by body plethysmography.
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in male than in female COPD patients, suggesting more
severe emphysema in men. Other investigators have re-
ported a more rapid progression of emphysema in fe-
males [12,32]. Gevenois et al. [35], did not find any
gender differences when they measured mean lung at-
tenuation in never-smokers. We found that women had
significantly higher lung density than men regardless
of smoking status, but the difference were no longer
present when adjustment for height in multivariate
models was made. Thus, the gender difference is prob-
ably anatomically related and suggests that women may
have more lung tissue per volume compared to men.
Smaller ribcage and shorter diaphragm in females are re-
ported previously [36]. We could not observe any gender
difference regarding BAL cell count or lung function
parameter including DLCO. Lower percentage of BAL
fluid recovery in male smokers may indicate different re-
sponse to cigarette smoke between genders.
Our study has some limitations. The number of partici-
pants with COPD was low, which makes the subgroup
analysis uncertain with regard to bronchitis and airways
obstruction. The clinical utility of CT for characterization
of airway obstruction in phenotypes with parenchymal de-
struction or mainly airway predominant disease has been
promising in some studies. However there is a consider-
able overlap between these phenotypes especially in ad-
vanced stages of COPD [37,38]. The question rises if
dividing our COPD patients in two main parenchymal and
airway predominant phenotypes produce more correct
correlation to inflammatory measurers in BAL in this
group. We deliberately included only COPD patients ofGOLD stage I and II to detect subtle parenchymal
changes. Secondly, measurement of small airways i.e. with
diameter less than 2 mm is difficult to perform accurately.
The lower attenuation limit of −900 HU considered to be
rational based on a report demonstrating pathological
specimens from patients with emphysema comprise more
voxels with attenuation lower than −900 HU [18]. Areas
with a density of -300 to -750 HU were calculated separ-
ately since this may represent pixels including tissue such
as small bronchi and vessels. Thus, we consider that areas
with a density of -750 and -900 HU represent lung tissue
with minimal interference from emphysema and denser
structures and this area can represent a good surrogate for
measuring the degree of local inflammation in the lung.
The inflammatory process in smokers is mainly concen-
trated in conductive airways (with diameter less than 0,
5 mm), lung parenchyma and alveolar space [8,39] and
cells recruited by BAL represent these areas. A lung at-
tenuation spectrum on CT which may represent these
corresponding areas is thus motivated. The fact that lung
density in the spectrum between −300 HU and −750 HU
did not differ between the three studied groups may indi-
cate that the inflammatory changes with impact on lung
density occur mainly in the conductive airways and in the
lung parenchyma.
Lung density is influenced by a number of factors in-
cluding the level of inspiration. To validate this important
factor we compared the total lung volume measured by
CT and the total lung capacity measured by body plethys-
mography. We found a good agreement in all three groups
indicating that the level of inspiration had a negligible ef-
fect on our results. Lung density was negatively correlated
to TLC but not age in never-smokers and this finding is in
agreement with a study from Gevenois et al. [35].
The strength of our study is that we included a group of
healthy never-smokers of both genders. Further, all mea-
surements, including CT scans and BAL, were performed
locally with same equipment and followed standardized
procedures. We believe that our results can be valuable
for selection of patients in research and clinical trials
dealing with CT and smoking associated pulmonary dis-
eases. By following attenuation trend inter-individually
it may be possible to determine when the preceding in-
flammation “switches” to emphysema. The findings may
help to interpret high resolution CT in the context of
smoking and gender and highlight the heterogeneity of
structural changes in COPD.
In conclusion, smokers have denser lungs than never-
smokers and females have denser lungs than males. The
density in smokers is associated to measures of systemic
inflammation and cell concentration in BAL. The results
support our hypothesis that smoking causes an inflamma-
tion in the lungs which can be quantified non-invasively
by means of CT density.
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